AJOG: In utero exposure to 17α-hydroxyprogesterone caproate and risk of cancer in offspring

ABSTRACT Background 17α-hydroxyprogesterone caproate is a synthetic progestogen initially approved in the 1950s to treat gynecologic and obstetrical conditions. Despite continued concerns about safety and short-term efficacy regarding the use…

Read More from AJOG: In utero exposure to 17α-hydroxyprogesterone caproate and risk of cancer in offspring

SMFM Statement: The Choice of Progestogen for the Prevention of Preterm Birth in Women with Singleton Pregnancy and Prior Preterm Birth

The Society for Maternal-Fetal Medicine (SMFM) has released a statement addressing the use of 17-alpha hydroxyprogesterone caproate (17-OHPC) therapy to prevent preterm birth (PTB) out of concern that women who…

Read More from SMFM Statement: The Choice of Progestogen for the Prevention of Preterm Birth in Women with Singleton Pregnancy and Prior Preterm Birth